Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
A sixth presentation on the company’s ctLNP platform will be discussed in an oral presentation on Saturday, May 11.
- A sixth presentation on the company’s ctLNP platform will be discussed in an oral presentation on Saturday, May 11.
- Generation Bio continues to leverage RES to advance its iqDNA platform by optimizing various structural and chemical elements.
- In new data presented at ASGCT, a second generation of iqDNA achieved higher luciferase expression than first-generation iqDNA.
- A copy of the presentation materials will be added to the “Our Scientific Presentations” section of the company’s website here on the day of each presentation.